Dezzutti C S, Frazier D E, Olsen R G
Ohio State University, Department of Veterinary Pathobiology, Columbus 43210.
Dev Biol Stand. 1990;72:287-96.
Three pig-tailed macaques were vaccinated twice, four weeks apart, with a human T-cell lymphotropic virus type 1 (HTLV-1) subunit vaccine. Four weeks post-vaccination, the vaccinated macaques and two control monkeys were challenged with a simian T-cell lymphotropic virus type 1 (STLV-1)-infected cell line. Following the first vaccination, an antibody response developed to HTLV-1 and STLV-1 viral proteins as visualized by Western blot. The antibody recognized both gag and env protein precursors and the titer remained elevated after the second vaccination. After challenge, the antibody titers of the vaccinates increased. The controls also developed HTLV-1 and STLV-1 specific antibody which recognized the gag precursor and to a lesser extent the putative tax protein. Immunized monkeys also produced syncytium inhibiting antibody primarily toward HTLV-1-infected cells and to a lesser extent toward STLV-1-infected cells. Control monkeys produced negligible amounts of syncytium inhibiting antibody. Additionally, both polymorphonuclear (PMN) and mononuclear (MNC) cells were examined. The PMN population was tested for its ability to generate an oxidative burst. Neither vaccination nor challenge had any significant effect on the PMN CL response. The MNCs were tested for their capability to proliferate after stimulation. Again, no significant change occurred. However, when examined for cell-mediated cytotoxicity, the MNCs from immunized monkeys produced greater cytotoxic activity against the HTLV-1-infected cell line than the MNCs from control monkeys. In order to determine if the immunized monkeys were protected by the subunit vaccine against the STLV-1 challenge, reverse transcriptase (RT) activity was measured in the five monkey's MNCs. RT activity was exclusively present in the non-immunized, control monkeys implying that the HTLV-1 subunit vaccine was successful in protecting the pig-tailed macaques from the STLV-1 infection.
三只食蟹猴间隔四周接受两次人嗜T淋巴细胞病毒1型(HTLV-1)亚单位疫苗接种。接种疫苗四周后,对接种疫苗的猕猴和两只对照猴用猿猴嗜T淋巴细胞病毒1型(STLV-1)感染的细胞系进行攻击。首次接种后,通过蛋白质印迹法可见针对HTLV-1和STLV-1病毒蛋白产生了抗体反应。该抗体识别gag和env蛋白前体,第二次接种后抗体滴度仍保持升高。攻击后,接种疫苗动物的抗体滴度增加。对照猴也产生了识别gag前体以及在较小程度上识别假定的tax蛋白的HTLV-1和STLV-1特异性抗体。免疫的猕猴还主要针对HTLV-1感染的细胞产生了抑制合胞体的抗体,对STLV-1感染的细胞产生的抑制合胞体抗体较少。对照猴产生的抑制合胞体抗体量可忽略不计。此外,对多形核(PMN)细胞和单核(MNC)细胞都进行了检查。检测了PMN群体产生氧化爆发的能力。接种疫苗和攻击对PMN的CL反应均无显著影响。检测了MNC在刺激后增殖的能力。同样,未发生显著变化。然而,在检测细胞介导的细胞毒性时,来自免疫猕猴的MNC对HTLV-1感染的细胞系产生的细胞毒性活性比来自对照猕猴的MNC更高。为了确定免疫的猕猴是否受到亚单位疫苗的保护而免受STLV-1攻击,在五只猴子的MNC中测量了逆转录酶(RT)活性。RT活性仅存在于未免疫的对照猴中,这意味着HTLV-1亚单位疫苗成功地保护了食蟹猴免受STLV-1感染。